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Precision medicine based upon molecular testing is heralded as a revolution in
how cancer is prevented, diagnosed, and treated. Large efforts across the world
aim to conduct comprehensive molecular profiling of disease to inform preclinical
models, translational research studies and clinical trials. However, most studies have
only been performed in patients from high-income countries. As the burden on
non-communicable diseases increases, cancer will become a pressing burden across
the world, disproportionately affecting low-middle income settings. There is emerging
evidence that the molecular landscape of disease differs geographically and by genetic
ancestry, which cannot be explained by environmental factors alone. There is a lack
of good quality evidence that characterises the molecular landscape of cancers found
in low-middle income countries. As cancer medicine becomes increasingly driven by
molecular alterations in high-income settings, low-income settings may become left
behind. Further efforts on an international scale must be made by researchers, funders,
and policymakers to ensure cancer research addresses disease across the world, so
models are not limited to subtypes of disease found in high-income countries. In this
review, we discuss differences found in the molecular profiles of tumours worldwide
and the implication this has for the future of global cancer care. Finally, we identify
several barriers currently limiting progress in this field and innovative solutions, which
may address these shortcomings.
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INTRODUCTION
The incidence of cancer across the world is increasing, with the number of new cases set to rise by
70% in the next 20 years (1). This rise in incidence is accompanied by a sharp increase in cancer
mortality, which disproportionately affects patients in low-middle income countries (2). As the
global burden of communicable disease decreases with improvements in prevention, sanitation
and treatment, non-communicable diseases such cancer will become a pressing burden. Whilst
low and middle-income countries (LMICs) contend with barriers, such as delays in accessing
healthcare, advanced disease at presentation, and limited access to treatment; research, and clinical
practice in high income countries (HICs) is aimed toward developing treatment strategies tailored
to individual patient characteristics and tumour biology.
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Revolutionary polyomic (genomic, epigenomic,
transcriptomic, proteomic, Figure 1) technologies have
become established in clinical research and are increasingly
commonplace in clinical practice in HICs. These technologies
are set to revolutionise how research is performed and how
therapies are selected—bringing precision medicine closer to
reality than ever before. Indeed, the pharmaceutical industry
are producing new agents designed to target specific molecular
subtypes of disease. New prognostic modelling techniques,
incorporating molecular data, clinical data and machine learning
will provide more information to inform treatment choices for
both patients and clinicians.
These evolving capabilities are set to transform outcomes,
however, there is little consideration given to how these
technologies can improve cancer outcomes across the world
and applicability to LMICs. Despite these remarkable advances,
most research and clinical trials are conducted on populations
within HICs, thus limiting global generalisability. There is
clear evidence that basic cellular processes vary across different
human populations (3, 4). Despite this, only 3% of genome-wide
association studies have been performed in Africans, without
considering sequencing studies (5, 6). Evidence in HICs from
studies comparing individuals from different ancestries has
found that despite controlling for socioeconomic factors and
other environmental exposures, there is still a large disparity in
cancer incidence and outcomes that remains to be addressed
(7, 8). To prevent advances in technologies creating even greater
disparity in cancer care across the world, work must now be
expanded to include low and middle-income settings.
CANCER IN LOW AND MIDDLE-INCOME
SETTINGS
Across the spectrum of country development and geography,
there are marked differences in the burden of cancer-related
disease. Compared to well developed countries, LMICs have a
higher age-standardised rate of gastric, oesophageal, bladder and
liver cancers (Table 1). Although LMICs appear at present to
have lower rates of lung, colorectal, pancreas and haematological
malignancies, the 2016 Global Burden of Disease study has
identified sustained rises between 1990 and 2016 of healthy years
of life lost to these cancers (2).
This socio-economic and geographical variation in causes
of cancer across the world has implications for both clinical
practice and future research. This difference in disease profile
is multifactorial (Figure 2) and includes environmental
factors, infectious agents (i.e., hepatitis B (HBV), hepatitis
C (HCV), Human Immunodeficiency Virus (HIV), and
Helicobacter pylori), occupational exposures and other lifestyle
factors (smoking, alcohol use) amongst others. In addition
to considerable differences in these risk factors, lower levels
of resources for healthcare and education result in patients
presenting to healthcare facilities with advanced disease in less
developed countries.
It is important to consider the context of cancer disease in
LMICs can be somewhat different to developed settings and the
implications this has. In this review we will explore how the
molecular aetiology and epidemiology of cancer in less developed
settings may differ and explore the impact this has for the future
of clinical practice and research.
MOLECULAR DIVERGENCE IN CANCER
AETIOLOGY
Evidence suggests there is variation in both somatic, germline,
and epigenetic alterations found across different human
populations (3, 4). What is emerging suggests there are key
genetic differences in some solid tumours when disease found in
LMIC countries is compared to that in HICs (9–13).
In both African and middle-eastern countries, germline
mutations in loci predisposing to breast, ovarian and colorectal
cancer have been characterised in a small number of studies
(14–19). In breast cancer for example, mutations in the BRCA1
and BRCA2 genes are more commonly found, with one Nigerian
study identifying mutation rates of 7.9% for BRCA1 and
3.1% for BRCA2—far higher than in the cancer genome atlas
(TCGA), where these are 1.3 and 1.5% respectively (16). Evidence
from Tunisia and Morocco is concordant, with a higher rate
of BRCA1/BRCA2 mutations, with some found to be novel,
previously uncharacterised, of unknown clinical significance
(14, 18, 20).
The same holds true for colorectal cancer, where there is little
population-level data surrounding the prevalence of germline
mutations in common cancer susceptibility genes. Germline
mutations reported in the literature from African countries
suggest that these variants are typically different from those
found in HICs and the clinical significance of these mutations
remains poorly characterised (7, 21–23).
Somatic and germline alterations across tumour types are
not exclusively limited to low-middle income countries; racial
disparity in the molecular composition of tumours also affects
patients in HICs. Within the United States, for all cancers
combined those of African-American ethnicity have been found
to have mortality rates up to 25 percent higher than in Caucasian
Americans (24). Several studies from TCGA and others have
identified several key alterations in the somatic landscapes of
tumours from African-Americans or Asian patients for renal,
endometrial, breast, head and neck, colorectal, cervical and
prostate cancers (25–29). Frequently, the differences in the
mutational landscape of these tumours are in pivotal cancer
driver genes, such as the von Hippel-Lindau (VHL) gene in clear
cell renal cancer (26).
Furthermore, oncogenes are found to be differentiallymutated
in different ancestral groups, for example in endometrial cancer
where PTEN mutations were found to predominate in those
of Caucasian or Asian descent, whereas in African-Americans
TP53 mutations are more common. These variations across
ancestral groups extend to the nucleotide level, with mutational
signatures having significantly divergent nucleotide signatures
when compared to mutations found in Caucasian populations
(27). Several initiatives are underway to address this, such as
the American Association for Cancer Research (AACR) 2020
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FIGURE 1 | Overview of molecular technologies for enabling precision medicine.
FIGURE 2 | Overview of sources of disparity in future cancer care across the world.
by 2020, which aims to sequence matched normal tissue and
tumour for 2020 African-American cancer patients by 2020 (30).
It is unclear whether the 2020 by 2020 initiative would utilise
whole exome or whole genome sequencing. The latter would
give a far richer pool of information on which to base further
studies upon.
Globally, projects aimed at defining the human genome and
cancer biology on a regional basis are beginning to emerge.
For example, the International Cancer Genome Consortium
(ICGC) is aimed at developing a comprehensive description
of genomic, transcriptomic and epigenomic changes in 50
tumour types, with data from 16 countries already included
(31). Recent publications have characterised the whole genomes
of 560 breast cancers, demonstrating more than 90 mutated
cancer genes were implicated in carcinogenesis, and that the
mechanisms underlyingmost mutational signatures are presently
unknown (32, 33). Unfortunately, LMICs (i.e., sub-Saharan
Africa) are poorly represented within the project, as with many
international genome collaborations, which limits conclusions
and applicability on a truly global scale.
Pharmacogenomics
Genetic polymorphisms affecting the metabolism of
chemotherapy drugs may also be different across different
ancestral groups. Differences in frequencies of functional genetic
variants in key drug response and metabolism genes may
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TABLE 1 | Relative increases in cancer burden by income setting.
Cancer HIC number
of cases 1990
LMIC number
of cases 1990
HIC number
of cases 2016
LMIC number
of cases 2016
Fold change
HIC
Fold change
LMIC
Breast cancer 467198 70634 726622 190102 1.56 2.69
Tracheal, bronchus, and lung cancer 476710 72750 746752 159990 1.57 2.20
Stomach cancer 256111 98378 292833 136618 1.14 1.39
Colon and rectum cancer 477269 47737 792174 112741 1.66 2.36
Other neoplasms 96362 39052 247574 105289 2.57 2.70
Liver cancer 80650 46993 189298 91647 2.35 1.95
Prostate cancer 419216 25137 899317 74721 2.15 2.97
Pancreatic cancer 99603 18608 192036 39197 1.93 2.11
Bladder cancer 133992 14391 213500 34771 1.59 2.42
Kidney cancer 92384 9864 160805 25876 1.74 2.62
Uterine cancer 89318 12357 188007 25635 2.10 2.07
Malignant skin melanoma 83987 2293 211113 5763 2.51 2.51
Global Burden of Disease estimates for cancer incidence (raw case number) in High SDI (HIC) and Low Middle Income (LMIC) countries in 1990 and 2016. Fold change in these is
displayed in right hand columns. Considerable rises in cancer incidence in LMICs can be seen.
significantly influence drug response differences in different
populations (34–37).
Evidence from LMICs across the world is sparse, however,
studies examining ethnic groups within HICs has identified
substantial differences in treatment response and toxicities
across ethnic groups. Understanding how these polymorphisms
affect treatment response and side effects is important if
precision medicine strategies are to be successfully implemented
worldwide. These polymorphisms found across different ethnic
populations can be beneficial or harmful. For example,
African-Americans are more likely to have variants of the
DPYD and TYMS genes which predispose this group to
haematological toxicities with 5-fluorouracil as compared to
Caucasian-Americans (38). Conversely, with 5-fluorouracil,
Caucasian-Americans are more likely to suffer diarrhoea,
nausea, vomiting, and mucositis when compared with their
African-American counterparts. A similar picture is true in
the metabolism of Doxorubicin, where African-Americans are
more likely to suffer cardiotoxicities than Caucasian-Americans.
Polymorphisms found in those of African ancestry may lead
to life-threatening toxicities, such as neutropaenia. A fall in
neutrophil counts following chemotherapy is more commonly
found in patients of African-American and Asian descent
when compared with Europeans (39). This may be due to
a constitutionally lower neutrophil count (in the absence of
cancer therapy), which has been associated with the presence of
the Duffy antigen/receptor chemokine gene (DARC) rs2814778
SNP in a study examining 261 healthy volunteers (40).
Several small studies examining the cytochrome P450, have
identified polymorphisms across ethnic groups (41). Diversity
in alleles of P450 is greatest across the African continent,
compared to in Europe, and Asia. Where the CYP2B6, CYP2C8,
CYP2D6, CYP2D6, CYP2D6, CYP3A5, and CYP3A5 have
greatest diversity. Drugs associated with varied metabolism in
the presence of polymorphisms affecting these genes include
cyclophosphamide (CYP2B6∗6), paclitaxel (CYP2C8∗2) and
5HT3 receptor antagonists (CYP2D6). Despite this, the clinical
implications these polymorphisms have for cancer therapy in the
context of LMICs are poorly characterised. The polymorphisms
found across these populations should be considered in the
context of the healthcare infrastructure available. If patients
in LMICs have similar diversity in polymorphisms associated
with drug metabolism, then consideration must be given to
the risk of exposing these patients to serious chemotherapy
toxicities. Work is currently underway to try and identify
polymorphisms associated with the metabolism of drugs found
on the WHO’s essential medicines list, beginning with HIV,
which could be extended into cancer therapeutics and provide
useful information to those administering treatments in LMICs
(34, 42). Whole-genome precision medicine approaches to
pharmacogenomics at the individual patient level are likely
to be some way off, however, a precision medicine approach
to public health could have significant advantages. In some
ways, this population level consideration of the genetic diversity
within a given population has started to occur. For example,
in Ethiopia studies have revealed that a high proportion of
the population are rapid codeine metabolisers due to CYP2D6
polymorphisms, leading to rapid conversion of codeine to
morphine and subsequent overdose at therapeutic doses (100).
MOLECULAR DIVERSITY AFFECTING
COMMUNICABLE CAUSES OF CANCER
Communicable diseases contribute toward a considerable
proportion of the cancer burden in LMICs. These are potentially
preventable cancers, with infectious agents commonly arising
from poor sanitation, vertical transmission (mother to child),
horizontal transmission (person to person) and a lack of safe
healthcare practices (i.e., needlestick injuries and reused sharps).
Examples include infectious agents such as Hepatitis B Virus
(HBV), Hepatitis C Virus (HCV), Human Immunodeficiency
Virus (HIV), human papilloma virus (HPV), and Epstein-Barr
virus (EBV), which are well known for their oncogenic potential.
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Prevention programmes over the past 20 years have increasingly
begun to recognise this, and vaccination programmes aimed at
preventing hepatitis B have been shown to be effective in reducing
the incidence of hepatocellular carcinoma. Similar can be seen
for HPV vaccination, where programmes have begun to be rolled
out in an increasing number of LMIC settings (43). Despite these
initiatives, little is known as to the molecular landscape of these
organisms and subsequent host-pathogen interactions.
Hepatocellular Carcinoma (HCC)
The effects of viral hepatitis on the development of hepatocellular
carcinoma is well characterised in HICs. With global vaccination
programmes aimed at preventing HBV underway, we may
observe a decrease in HBV associated HCC. Despite this, HCC
is multifactorial and infection with HCV or other causes of
cirrhosis typically contribute to the risk of HCC development.
The somatic landscape of HCC has been well characterised
in American, European, Chinese and Japanese populations;
however, evidence is lacking on disease found in LMICs (44, 45).
The practicalities HCC poses to obtain tumour samples in LMICs
are challenging, primarily owing to the risks associated with liver
surgery and very late stages of presentation.
The distribution of HBV and HCV across the world has
substantial variation and drive HCC formation in separate
manners. HBV has a higher prevalence in LMICs and is
responsible for the majority (%) of virus-induced hepatocellular
carcinoma, compared with HCV (%) (46, 47). Dysregulation of
key cell-cycle proteins, including cyclin dependent kinase 2 and 4,
upregulation of the RAS/MAPK/ERK pathways andmaintenance
of upregulated canonical Wnt signalling, on the background of
chronic inflammation are believed to initiate and drive HCV-
related hepatocellular carcinoma (HCC) (48). HBV integrates
within the host genome, initiating HCC through the promotion
of genomic instability (49, 50).
Different genotypes of the Hepatitis C virus are known to lead
to higher risk of HCC (51). Classically, the type 1b genotype has
been associated with the highest risk of HCC formation. The
global prevalence of HCV genotypes and variation worldwide
has been studied in detail. Modelling studies demonstrate a high
level of variation across the world in genotype, even within
continents (46). Type 1 HCV predominates worldwide, however
in central and west Africa, type 4 is more commonly found.
Little data is available on why this variation exists and how
this may reflect in disparity in HCC rates worldwide (46). In
particular, study of genotype 4 and how this type mediates HCC
formation in LMICs is missing. Host-pathogen interactions are
known to play a crucial role in the clearance of these viruses
and hence the subsequent risk of developing virus associated
HCC. It is well known that patients of African ancestry have
lower viral clearance rates than Caucasians (52). Several genome-
wide association studies performed on patients of African descent
have identified polymorphisms in alleles near class II Human
Leukocyte Antigens on chromosome 6, the IL28B gene and other
SNPs (53–56). This evidence draws upon a limited number of
participants from LMICs and does not study the subsequent
likelihood of HCC development.
The interaction between environmental and genetic factors
may have a significant influence on the risk of HCC. The study
of these interactions is limited in LMICs, however there are
some examples of where this has been proven to be successful.
Environmental exposures such as Aflatoxin B1 (found in certain
grains and funghi), alcohol use, obesity, amongst others are
known to contribute (57, 58). The interaction between Aflatoxin
B1 and host genetics is particularly interesting: Aflatoxin B1
exposure is associated with HCC expressing more p53 mutations
than in unexposed patients and may lead to greater genomic
instability. Aflatoxin B1 has synergy with HBV, promoting
HCC formation (59). Strategies to identify ways to abrogate
DNA damage exerted by Aflatoxin B1 are under investigation
and other environmental exposures are currently under study.
Nevertheless, owing to little data on the molecular landscape of
HCC in LMICs, it is unclear whether these research findings will
have benefit for these patient groups. Similar epidemiological
association studies have been done for other cancers, however,
the data which provides the basis for disease models and
translation to clinical practice in LMICs is lacking.
Cervical Cancer
Cervical cancer disproportionately affects women in LMICs,
with the highest incidence found in sub-Saharan Africa (1, 60).
Cervical cancer deaths are higher in LMICs, with 9 out of
10 deaths from cervical cancer worldwide occurring in LMIC
settings. At present radiotherapy and surgery are the mainstays
of cervical cancer management. The cause for this disparity in
cancer incidence across the world is poorly understood and
is multifactorial. Availability of radiotherapy in LMICs is also
known to be extremely limited (61).
A proportion of cervical cancer cases are preventable, through
early identification of dysplastic disease and immunisation
against HPV. There are close connections with HIV too, with
women who are HIV at a higher risk of developing cervical
cancer. The prevalence of HPV is higher in women in LMICs
than in HICs (62). There is a particularly high prevalence in
Africa and Oceania, with higher exposure at a younger age.
This in part accounts for the higher burden of cervical cancer
in LMICs and the epidemiological burden of HPV associated
cervical cancer is well described. In HIC populations genetic
associations have been associated with the development of
cervical cancer and are relatively well characterised (63, 64).
Host-pathogen interactions between HPV and the immune
system are also relatively well-characterised with respect to
disease found in HICs. In HICs, genes such as TGF-β, those
governing toll-like-receptors (TLRs), MHC genes and expression
of cytokines, intricately linked with immune responses are
associated with effective clearance of HPV (65–67). The somatic
landscape of these tumours in LMICs is poorly characterised.
Evidence in LMICs suggests polymorphisms on the TYMS
and RPS19 genes are associated with high-risk infection in
Nigerian women, but overall in LMICs evidence is lacking
on factors influencing effective HPV clearance (68). Several
studies of women in HICs of African ancestry have identified
that women of African-American descent despite having a
similar prevalence of HPV, take longer to clear the virus (69).
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This delayed clearance, combined with known polymorphisms
affecting genes responsible for immune response may go some
way to explaining the higher rates of cervical cancer in LMICs
(70). Further evidence is emerging that the distribution of HPV
genotypes differs across separate geographical locations, with
HPV 16 predominating worldwide, but HPV 58 and 31 more
commonly found across Africa and East Asia. HPV 58 has been
associated with increased risk of cervical cancer (71). Despite this
work, there are scarce data from studies into virus genotype and
genome-wide factors that may drive cervical cancer in LMICs.
BARRIERS TO GLOBAL RESEARCH IN
PRECISION MEDICINE
Genetic variation through germline polymorphisms and somatic
mutations associated with cancers in LMIC populations,
suggests there may be opportunity for implementing global
strategies for more effective individualised treatment and better
prognostication. In HICs, molecular testing is already being used
to target therapies to specific alterations in tumours. Examples
of this include the use of trastuzumab following HER2 testing
in breast cancer, use of endocrine therapy in breast cancer
and guiding EGFR targeted therapies in colorectal cancer using
KRAS testing. In the case of colorectal cancer, both type and
location of KRAS mutations are known to predict response
to EGFR inhibition in colorectal cancer (72). There is some
limited evidence to suggest EGFR/KRAS mutations occur in a
similar pattern and distribution in LMICs as compared to HICs
(22, 73, 74). However, in African-American populations within
HICs, there is an increased frequency of mutations found in
genes implicated in EGFR signalling, which may correspond with
more aggressive disease (75, 76). Despite this, no clinical trials
have aimed to include patients within these settings or sequence
tumours to identify predictors of response. Building evidence to
support precision medicine at a global level is important, both
in terms of providing effective cancer therapies and being able to
decide whether targeted therapies are cost effective in LMICs.
Building a sustainable workforce of clinicians, laboratory
medicine and scientific leaders in this field is key. At present,
in LMICs, implementing effective national programmes
for precision cancer therapy and prevention following
similar models to examples within HICs is unlikely to be
feasible. A lack of trained laboratory medicine workforce,
instruments, transportation, finances, and evidence to support
the applicability of clinical response are all key factors (77–79).
Access to pathology and laboratory medicine services in their
current format is a major issue, with some LMICs having no
workforce at all (77, 78). To support the implementation of
precision medicine approaches to therapies, there is a pressing
need to change this and ensure the emerging workforce have
the skills to support the transition to precision medicine in
these settings. Alongside the development of cancer therapies
and research models, delivery of increasingly complex therapies
requires major improvements in healthcare infrastructure and
resource and it is optimistic to say that workforce development
alone will enable this. Establishing infrastructure to support
translational research in LMIC settings has challenges. The use of
regional biobanks may provide a method to collect tissue samples
now, for processing later, when infrastructure is in place, or
even to demonstrate feasibility of systematic tissue collection—
derisking investments that would otherwise have been spent on
building an entire sample handling and sequencing pipeline.
Biobanks, however, require large amounts of energy resources
to ensure samples are frozen, with some biobanks using liquid
nitrogen to freeze samples. Liquid nitrogen transport is difficult
in HICs, let alone securing a reliable supply in LMICs. Electricity
supplies in some LMIC locations is sporadic too, which would
be required to operate freezer systems. Other preservative
solutions could be used to preserve nucleic acids in tissues
at room temperature as a stop-gap solution, or as a means of
extending the time available to transport specimens to a central
repository. Transporting biospecimens and tissue is subject
to tight United Nations control, thus making international
efforts more difficult for countries without existing expertise
to contribute. Furthermore, times of epidemic and regional
spread of disease has implications for whether it would be
safe to transport biospecimens across the world. Further issues
surrounding the logistics remain and policy makers should
identify solutions to this as a priority.
Global Cancer Trials
Conducting high-quality cancer trials is challenging in high-
income settings and even more so in locations with little
clinical trial infrastructure (80). Considerable methodological
challenges exist around patient stratification by treatment
response. Biomarker identification and sample handling must
be robust and timely, together with the requirement for
high levels of patient follow-up. In all countries, undertaking
follow-up, and transporting biological specimens is challenging.
These challenges are amplified in LMIC settings, with many
countries lacking postal address systems, patient records and
the infrastructure to process clinical specimens. Furthermore, a
supply of clinical triallists is short in LMIC settings. Training
and exchange programmes with HIC partners may help provide
solutions in the sohrt term, however, long term infrastructure
building must be given priority.
One example of where this is changing is Rwanda, where
electronic patient record systems are being introduced (81).
Integrating clinical systems into research in such settings would
enable efficient research to be undertaken. In HICs, registry-
based trials provide an efficient means of producing follow-up
data and this approach could be emulated in LMICs where
electronic records exist. A further consideration to any future
trials of precision in LMIC settings is whether this can be
continued after the trial concludes, should an intervention prove
effective. For this reason, details on sequelae of interventions
should be collected to ensure health-care systems can handle any
treatment related harms. Non-governmental organisations such
as the World Health Organisation and other non-governmental
organisations (NGOs) often perform scoping studies in LMIC
countries, but few cancer specific trials have been iniated. These
NGOs should consider whether building research infrastructure
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in medicine is a sufficient priority to enable tailored solutions to
be led by LMIC investigators independently.
In other areas of medicine (such as malaria, HCV and
HIV) have successfully delivered clinical trials that integrate
molecular or genotypic testing to enable molecular determinants
of disease response to be identified in LMICs (82). Malaria is a
good example, where trials often collect data on genotypes and
information on microsatellites of malaria parasites from DNA
isolated from blood films or spots. The markers used can be
tested in a polymerase chain reaction (PCR) assay by research
staff at that centre. Malaria trials have used these to investigate
markers of treatment resistance and response (83, 84). Similarly,
for trials in antiretroviral therapy for HIV and HCV, there are
several studies which utilise commercial molecular testing kits at
the centre level for identifying genotypes found in disease (85).
However, this approach is challenging to adopt and thought must
be given to the sustainability of testing when it is attempted to
adopt trial findings into routine clinical practice.
Capacity Building for Precision Medicine
The most notable effort currently underway in LMICs to build
evidence and crucially capacity for genomic sequencing is the
Human Heredity and Health in Africa initiative (H3Africa) (86).
This project is a collaboration of African clinicians, scientists
and bioinformaticians who conduct large-scale sequencing and
genetic association studies. So far, they have largely focussed on
communicable disease such as trypanosomiasis, stroke and other
neurological diseases affecting patients across the continent.
Relevant to the field of oncology, some work has been undertaken
into HPV infection in Nigeria (68), with the women included
in this study demonstrating similar genetic susceptibility to
infection as other populations. This group are set to expand
into the field of breast cancer, which will provide useful data to
study the genomic epidemiology of the disease on the African
continent. The MRC Centre for Genomics and Global Health
in the Gambia has also conducted successful genome wide
and sequencing techniques in other disease areas, including in
P. falciparum (87, 88).
There have been several success stories in LMICs, with
some African countries delivering exciting genetic epidemiology
studies. The Nigerian Breast Cancer Study, led by the University
of Idaban has produced several large studies, underpinning the
understanding of breast cancer genetics in Nigerian women (89).
Through collaborative support from the University of Chicago,
this group has gone on to publish multiple genetic epidemiology
studies, and have even attempted randomised clinical trials (90).
Building partnerships between institutions with experience in
polyomics may help foster knowledge exchange and promote the
implementation of best practice.
Local Lead and Oversight of Research
Projects
Any solution must be led and maintained locally, rather than
researchers from HICs taking data from local populations. It
must also maintain practicality and clinical relevance to the
local patient population. The H3Africa initiative has recently
published guidelines for researchers wishing to do research in the
African continent which are aimed at empowering local scientists
and ensuring benefit for African patients (5). Developing home-
grown expertise in polyomic technologies in LMICs would
also have economic benefits in addition to building the global
laboratory medicine workforce of the future. In fact, LMICs
may be at some advantage in building competitive platforms for
precision medicine as they can adopt new technologies without
having to make mistakes or go through the intermediate steps of
technological evolution that have been observed in high-income
settings.
Disruptive Near-Future Technologies
New technologies may provide innovative solutions to some
of the barriers to precision medicine. Genome sequencing
over the past 15 years has fallen by 100,000-fold, yet with
the cost of sequencing an entire human genome around
the region of $1000, this is still prohibitively expensive for
patients and healthcare systems (91). Furthermore, the sample
handling and analysis pipelines required to support genome
sequencing is logistically challenging. Establishing infrastructure
and identifying expert staff to deal with sequencing data and
ensure appropriate quality control is a large barrier. Large
quantities of computational resource are required and may
work as a centralised resource across, if shared across multiple
LMICs. Whilst a centralised model may be a more cost and
resource effective model, other challenges, including specimen
transportation, and political stability could pose barriers to such
a model. Furthermore, models of research and practice must be
sensitive to resources of countries involved (Figure 3). Examples
such as nanopore sequencing devices may provide an answer
to these logistical challenges, with handheld and smartphone
based sequencing devices available which reduce requirements
for library preparation (92, 93). This has the potential to enable
targeted sequencing of patients, at a far lower cost. With other
multiplexing approaches, including developments in nucleotide
barcoding, many samples could be rapidly processed at a very low
cost.
Targeted sequencing and mutation detection assays (PCR
or ligation based methods, Table 2) offer a good alternative,
but require that there is data to support that these assays
bring clinical benefit, often derived from sequencing data.
New, more portable approaches to molecular testing are being
developed, which may be useful in resource-limited settings.
Paper-based oligonucleotide based ligation assays, originally
developed to detect HIV genotypes and monitor resistance,
could be adapted for use in cancer therapy (94, 95). Paper-
based immunochromatography assays, popularised for detection
of HIV, could also be adapted for the detection of cancer specific
ligands at the point of care. Nevertheless, these approaches lack
the ability to resolve molecular alterations at the nucleotide level
and rely on these already being known. The potential impact
for these assays is great, particularly in the context of cancer
diagnosis in limited resource settings, where other common
diagnostic tests such as endoscopy or imagingmaybe unavailable.
Promising developments are on the horizon for the
diagnosis and monitoring of disease, such as liquid biopsy
and measurement of circulating nucleic acids (circulating
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FIGURE 3 | Proposed models of future deployment of precision medicine across world.
tumour DNA/ RNA) (96). At present, these technologies rely
of measurement of small quantities of nucleic acids, circulating
tumour cells or other targets in peripheral blood via sequencing
and subsequent computational processing (97). Although a
reliable and universal test is yet to be developed based on this
methodology, the development of such a test has the potential to
improve early diagnosis and reduce reliance on other expensive
methods of diagnostic testing in LMICs. However, given the
lack of workforce, infrastructure and expertise available in
LMICs at present, new technologies may further exacerbate
global inequalities. Similarly, for other biomarkers of cancer
which could be utilised as substrates to bind ligands to deliver
cancer therapies with (such as fluorescence imaging (98),
chemotherapeutics, or radiotherapeutics), there is little data to
support whether what works in HICs can be translated straight
into LMICs safely. Indeed, at present there is very little data
that underpins the patient pathway or outcomes after cancer
treatment in LMICs.
Collaborative approaches are crucial to ensuring future
success (80, 99). Several partnerships between HICs and LMICs
have begun to collect prospective, high quality evidence and
establish clinical research networks. One such example is the
GlobalSurg collaborative, a network of over 5,000 surgeons
throughout the world who deliver large multicentre prospective
studies (100). Recently, this network has established several trials
units in LMIC settings that will deliver cancer trials and test
whether new devices being concurrently developed in HICs can
be utilised in LMICs. Building sustainable capacity concurrently
with new developments will enable local economies to thrive
and patients in LMICs to receive cutting edge care. Working
with LMIC partners to facilitate global translation should be a
priority when developing potentially disruptive technologies for
both researchers and industry.
SUMMARY
Funders, scientists, genome consortia, scientific journals and
policy makers have an important role to play in a drive to
ensure cancer research is generalisable across the world and will
benefit patients in LMICs. Many major journals now mandate
that polyomic data is deposited in databases for future use by
the scientific community and other interested partners. This
has been highly successful, with databases such as RNAcentral
containing 13 million sequences and the ICGC Project available
to the worldwide scientific community (31, 101). In addition,
collaboratives such as the 1,000 genome project, containing 2,500
human genomes and representing 26 populations, demonstrate
the growing potential to sequence genomes on a global scale
(102). However, most data currently deposited is from HICs
and more work is required to increase the availability of
data from LMICs. Funders have begun to recognise this, and
recent discussions have begun to focus on building precision
medicine at a population level in LMICs (5, 103). At present,
this initial funding is focussed on precision medicine for
communicable disease, despite the rising burden of non-
communicable disease.
Precision medicine clearly offers numerous advantages for
patients and recent efforts to characterise the landscape of cancers
using polyomic technologies is changing research and practice.
There is, however, a lack of evidence, data and clear strategy
on how this will be used to benefit patients across the world,
particularly in LMICs. Emerging evidence suggests there are
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TABLE 2 | Possible enabling technologies for global precision medicine.
Technology Pros Cons Barriers to implementation of
technologies to LMIC settings
Whole-genome sequencing
(Sequencing-by-synthesis
or ion semiconductor
sequencing)
• High-throughput and high-speed
• Well developed technology
• Sequencing pipelines can be developed
with ‘off the shelf’ solutions
• Large body of global expertise
• Provides detailed, pangenome
information
• Deep sequencing would provide
unparalleled information on novel
variants (including non-coding)
• High cost
• Likely to require centralisation of
expertise due to lack of infrastructure
currently
• Sample preparation and library
generation required
• Sample logistics may be difficult from
the perspective of clinical care and
transporting sample to centralised
facilities
• Short reads
• Current lack of computational
infrastructure and expertise in
LMICs Likely to require international
cooperation - could be sensitive to
political instability Sample pipelines
would require careful planning and
implementation High cost
Exome-sequencing
(Sequencing-by-synthesis
or ion semiconductor
sequencing)
• Lower cost than whole-genome
• Still captures information on important
genes
• Typically faster than whole genome
sequencing
• Could be performed using a more
regional model of delivery
• Cheaper sequencing instruments to
deliver same depth as whole genome
• More clinically relevant as same
infrastructure could deliver targeted
clinical panels
• As above for whole genome sequencing
• Still relatively high cost
• Offers less coverage and no coverage of
non-coding elements
• As above for whole genome
sequencing
Direct sequencing
(Nanopore sequencing)
• Highly transportable
• Minaturised versions available that
require less computational infrastructure
than other sequencing approaches
• Lower cost than other sequencing
instruments
• Less sample and library preparation
• Can be used to directly sequence other
nucleic acids and proteins
• Easily expandable
• Very long read lengths
• Currently limited to targeted sequencing
studies in humans
• Currently marginally lower accuracy
than established semi-conductor and
sequencing by synthesis approaches
• Limited depth at present in humans
versus other approaches
• Clinically approved devices not yet
available
• Would require international
collaboration on how data is
pooled together and standard
operating procedures to ensure
quality control if many users and
devices used in a distributed model
• Current lack of computational
infrastructure and expertise in
LMICs
Other targeted panels
(i.e. microarray)
• Lower cost than sequencing
• High throughput
• Less computationally intensive
• Other applications i.e. cytogenetics
• Global expertise readily available
• Cheap instrumentation
• Biased detection methods
• Sequencing becoming increasingly
more popular
• Lower dynamic range for detection than
sequencing methods
• Cannot detect novel transcripts
• Would require international
collaboration on how data is
pooled together and standard
operating procedures to ensure
quality control if many users and
devices used in a distributed model
• Technology may be outdated and
superceded by sequencing
• Current lack of computational
infrastructure and expertise in
LMICs
Oligonucleotide ligation
assays/ Polymerase chain
reaction
• Very cheap
• Can be paper-based
• Transportable
• Limited scientific skills required
• Easily mass-produced
• Can only detect known variants in a very
simple fashion
• Not quantitative
• Requires substantial development
• Unclear how may be used with
heterogenous samples i.e. solid tumour
• Data not easily stored in electronic
format
• Would require sequencing or array
studies to validate targets of assays
prior to deployment
differences at the molecular level between cancer in HICs and
that found in LMICs. To ensure inequity in cancer care between
high and LMIC settings is not worsened, steps must be taken
to improve the mechanistic understanding of cancer at a global
level.
SUMMARY POINTS
• There is known variation in basic cellular processes such as
DNA methylation, epigenomic alterations and frequencies of
polymorphisms across different human populations. These are
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likely to affect cancer risk, disease behaviour and treatment
response.
• LMIC populations are under-represented in large genome
wide association studies and sequencing studies. In an era
where genomic technologies are driving drug development
and targeted therapies, this may result in global inequities for
cancer therapy.
• To prevent cancer inequities worsening further, funders,
researchers and scientists should aim to include patients
from LMICs in international studies. This would ensure that
emerging consensus molecular subtypes are representative of
disease worldwide.
• New technologies present exciting opportunities to improve
cancer care and the representation of LMIC countries in
cancer research. Further work should be done to ensure LMIC
representation and identify novel ways of implementing cost-
effective approaches to precision medicine or precision public
health within LMIC settings.
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